Year: 2017
Type: article
Abstract: Endogenous satiety hormones provide an attractive target for obesity drugs. Glucagon causes weight loss by reducing food intake and increasing energy expenditure. To further understand the cellular mechanisms by which glucagon and related ligands activate the glucagon receptor (GCGR), we investigated the interaction of the GCGR with receptor activity modifying protein (RAMP)2, a member of the family of receptor activity modifying proteins. We used a combination of competition binding experiments, cell surface enzyme-linked immunosorbent assay, functional assays assessing the Gαs and Gαq pathways and β-arrestin recruitment, and small interfering RNA knockdown to examine the effect of RAMP2 on the GCGR. Ligands tested were glucagon; glucagonlike peptide-1 (GLP-1); oxyntomodulin; and analog G(X), a GLP-1/glucagon coagonist developed in-house. Confocal microscopy was used to assess whether RAMP2 affects the subcellular distribution of GCGR. Here we demonstrate that coexpression of RAMP2 and the GCGR results in reduced cell surface expression of the GCGR. This was confirmed by confocal microscopy, which demonstrated that RAMP2 colocalizes with the GCGR and causes significant GCGR cellular redistribution. Furthermore, the presence of RAMP2 influences signaling through the Gαs and Gαq pathways, as well as recruitment of β-arrestin. This work suggests that RAMP2 may modify the agonist activity and trafficking of the GCGR, with potential relevance to production of new peptide analogs with selective agonist activities.
Source: Endocrinology
DOI: 10.1210/en.2016-1755
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,750
Funders: Wellcome Trust, National Institute for Health and Care Research, Royal College of Surgeons of England, Diabetes UK, Imperial College London, Novo Nordisk, European Association for the Study of Diabetes, Directorate for Biological Sciences, Medical Research Council, NIHR Imperial Biomedical Research Centre, H2020 European Research Council, FP7 Health
Awards: G1258311730, G1261368593, Multicellular regulation of insulin secretion from pancreatic islets, G2091352331, NIHR Senior Investigator Award, Do gut hormones mediate the beneficial effects of Roux-en-Y bypass surgery?, G2400843396, RAMP2 and the glucagon receptor: important in the pathogenesis of non-alcoholic fatty liver disease?, In situ imaging of beta cell function in mice deleted for Type 2 diabetes-associated genes, NIHR Senior Investigator Award, Are gut hormone changes why the long-limb gastric bypass is more effective than the standard-limb gastric bypass in improving type 2 diabetes mellitus?, All-optical deconstruction of the islet wiring patterns underlying insulin secretion in health and disease, Ligand bias at the GLP-1 receptor as a means of favouring cytoprotection, Developmental Clinical Studies - Curing Obesity with the 'Medical Bypass', G7005210393, Next generation Y analogue for treatment of obesity, G7712152596
OpenAlex ID: W2622192206
